IFNA2
Interferon alpha-2
Also known as: IFN-alphaA, IFNA, IFNA2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01563
- Gene
- IFNA2
- Ensembl
- ENSG00000188379
- Chromosome
- 9
- Canonical length
- 188 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]
Canonical amino-acid sequenceUniProt
188 residues, UniProt reviewed canonical sequence.
>P01563|IFNA2
1 MALTFALLVA LLVLSCKSSC SVGCDLPQTH SLGSRRTLML LAQMRRISLF SCLKDRHDFG
61 FPQEEFGNQF QKAETIPVLH EMIQQIFNLF STKDSSAAWD ETLLDKFYTE LYQQLNDLEA
121 CVIQGVGVTE TPLMKEDSIL AVRKYFQRIT LYLKEKKYSP CAWEVVRAEI MRSFSLSTNL
181 QESLRSKELocalizationUniProt · AlphaFold · HPA
Whether an antibody against IFNA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 0.2 nTPM
Expression across tissuesHPA
Tissue
- basal ganglia: 0.2 nTPM
- amygdala: 0.1 nTPM
- hippocampal formation: 0.1 nTPM
- midbrain: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
Single-cell type
- oligodendrocytes: 3.2 nCPM
- bergmann glia: 0.3 nCPM
- oligodendrocyte progenitor cells: 0.3 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
Immune cell
- eosinophil: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 3.6 nTPM
- white matter: 3.6 nTPM
- cerebral cortex: 2.6 nTPM
- thalamus: 2.3 nTPM
- amygdala: 2 nTPM
- hypothalamus: 2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- -0.99
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
InteractionsUniProt · HPA
Protein binding partners of IFNA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IFNA2 as an antibody target. Whether an autoantibody or antibody against IFNA2 could matter depends on whether native IFNA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IFNA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IFNA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...